CERo Therapeutics secures up to $11.67M senior secured note with SRX Global

CERO THERAPEUTICS HOLDINGS, INC.

Consolidates prior notes of $5,666,108.77 (SRX $2,794,000; Keystone $2,872,108.77) plus up to $6M additional advances.
Initial advance of $775,665 on Aug 27, 2026; proceeds for trade payables and working capital.
10% annual interest (24.99% on default); matures Oct 15, 2026; secured by subsidiary stock and all assets.
Subsidiary CERo Therapeutics, Inc. guarantees payment; collateral includes IP, patents, CER-1236 assets.

item 1.01 item 1.02 item 2.03 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.